Abstract
Purpose: To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort®) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma (NG).
Materials and Methods: Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been proposed to switch current IOP-lowering therapy to Ganfort®. In case target IOP level was not reached filtration surgery was recommended. Ganfort® administration - once a day in the morning.
Results: IOP-lowering has been observed in all patients when switched to Ganfort®. Mean IOP level was almost 3-x lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5 %) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment.
Conclusion: IOP-lowering fixed combination Ganfort® (Allergan) can be used in patients with secondary neovascular glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not achieved, Ganfort® can be administered in pre-operative period and helps to reduce postoperative complications.
Keywords: Neovascular glaucoma, diabetes mellitus, intraocular pressure, diabetic glaucoma.
Current Diabetes Reviews
Title:The Fixed Combination Efficacy Assessment in Patients with Secondary Neovascular Glaucoma and Diabetes Mellitus
Volume: 11 Issue: 4
Author(s): D. V. Lipatov, T. A. Chistyakov, A. G. Kuzmin and A. A. Tolkacheva
Affiliation:
Keywords: Neovascular glaucoma, diabetes mellitus, intraocular pressure, diabetic glaucoma.
Abstract: Purpose: To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort®) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma (NG).
Materials and Methods: Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been proposed to switch current IOP-lowering therapy to Ganfort®. In case target IOP level was not reached filtration surgery was recommended. Ganfort® administration - once a day in the morning.
Results: IOP-lowering has been observed in all patients when switched to Ganfort®. Mean IOP level was almost 3-x lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5 %) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment.
Conclusion: IOP-lowering fixed combination Ganfort® (Allergan) can be used in patients with secondary neovascular glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not achieved, Ganfort® can be administered in pre-operative period and helps to reduce postoperative complications.
Export Options
About this article
Cite this article as:
Lipatov V. D., Chistyakov A. T., Kuzmin G. A. and Tolkacheva A. A., The Fixed Combination Efficacy Assessment in Patients with Secondary Neovascular Glaucoma and Diabetes Mellitus, Current Diabetes Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573399811666150525121225
DOI https://dx.doi.org/10.2174/1573399811666150525121225 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism Mechanisms and Characteristics of Sulfonylureas and Glinides
Current Topics in Medicinal Chemistry Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews The Evolving Roles of Nuclear Cardiology
Current Cardiology Reviews A Review on the Development in the Field of NIDDM based Thiazolidinedione PPARγ Agonists
Mini-Reviews in Medicinal Chemistry Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Disseminated TB in an Immunocompetent Patient: A Case Report
Infectious Disorders - Drug Targets Subject Index To Volum 2
Current Diabetes Reviews Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Vitamin D Deficiency, Prevalence and Treatment in Neonatal Period
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Current Diabetes Reviews Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery